China Biologic Products Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From China Biologic Products Holdings, Inc.
Chinese healthcare and life sciences firms now overshadow their peers in Japan and India in terms of key valuation metrics amid COVID-19 and China has also witnessed significant M&A activity at high revenue multiples.
Within months, one of the three latest immuno-oncology drugs from Chinese firms Innovent, Junshi and Akeso is likely to be approved, providing new competition to global giants such as BMS and Merck & Co. as they race each other over to the finish line.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
- Large Molecule
- Other Names / Subsidiaries
- CBPO Holdings Limited
- CBPO Group Limited
- Guiyang Dalin Biologic Technologies Co., Ltd.
- Guizhou Taibang Biological Products Co. Ltd.
- Shandong Taibang Biological Products Co., Ltd.
- Tianxinfu Medical Appliance Co., Ltd.